A Single-arm, Non-randomized and Open-label Phase 3 Study Evaluating the Efficacy, Safety and Tolerability of Intravitreal Aflibercept in Japanese Patients With Neovascular Glaucoma (NVG)
Phase of Trial: Phase III
Latest Information Update: 05 Apr 2019
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Neovascular glaucoma
- Focus Therapeutic Use
- Acronyms VENERA
- Sponsors Bayer
- 03 Apr 2019 Status changed from recruiting to completed.
- 17 Oct 2018 Status changed from not yet recruiting to recruiting.
- 27 Aug 2018 New trial record